Periodic Reporting for period 1 - Volumizer (A natural, non-surgical, and safe facial filler which treats the root cause of facial ageing.)
Período documentado: 2018-01-01 hasta 2018-04-30
Close to 18.8 million cosmetic facial injections were performed in 2017 . This can be segmented into two demographics; approximately 90.8% of those procedures performed on women, & approximately 73.3% of treated individuals were between the ages of 35-64. Globally, people are getting more concerned on aging gracefully due to the increased social exposure, job competition, and readily available products on the market. Though there are a plethora of newly available facial injection fillers, nearly all of them lack in effectiveness while others have significant risk of side effects.
Volumizer as an effective and long term solution to the root cause of facial aging without the disadvantages.
Volumizer as an effective and long term solution to the root cause of facial aging without the disadvantages.
Between 1st January 2018 and 30th April 2018, we at PB&B undertook the Phase 1 Feasibility Study under the SME Instrument to determine the technical and economic viability of the Volumizer solution as a dermal facial filler injectable solution amongst the cosmetic and plastic surgery industry in Europe and globally. As a result of what we undertook and the key findings made, we confirm the technical viability and immense commercial value to be brought upon the European, U.S East Asia, and global stage. The assessment also confirmed the product’s feasibility for optimised scale up production in order to meet this global expected demand. As a result, the main findings as a summary include successfully validating our commercial value chain, determining our primary, first entry, and subsequent market segments, the business model to be adopted for optimum distribution, as well as the technical industrialisation requirements needed for eventual wide-spread commercial sales in Europe and globally.
The potential implications include full pursuit of the commercialisation activities described for the proposed project's follow-on execution. Primarily, the commercial feasibility being the main of many implications to the project's execution. This includes us defining a clear 'route to market' when taking into account the geographic segments that have responded best to our current development and pre-clinical work activities. On the wider scheme of things, this proposed project's successful introduction of Volumizer will receive a diverse array of patient candidates, especially from the more vulnerable elderly demographic. Being able to enjoy the benefits of naturally based, risk-free, and effective facial filling, first starting out in Switzerland and the EU, before expansion into the U.S and East Asia. In addition to these, we were also able to confirm the industrial scale up necessities of Volumizer, and clinical validation required for first sales in Europe - and follow-on actions required to make this a reality including the regulatory pathways and technical expertise needed for smooth execution and transition into first sales. In terms of disruption, Volumizer is poised to become a core replacement to existing facial fillers which have continued to underperform, and setting the new standard on what fast and effective facial filler treatment will be like.